 AIM ImmunoTech Inc NYSE:AIM told investors it expects to begin enrolling patients in the first quarter next year for a Phase 2 trial of its investigational drug Ampligen as a therapeutic for patients with post-COVID conditions following regulatory approval. The US Food and Drug Administration FDA have cleared the firms Investigational New Drug IND application for the drug AMP-518. 